Charles River Laboratories International (NYSE:CRL) Price Target Lowered to $190.00 at The Goldman Sachs Group

Charles River Laboratories International (NYSE:CRL) had its target price reduced by The Goldman Sachs Group from $220.00 to $190.00 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other equities analysts have also weighed in on the company. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Redburn Atlantic assumed coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. Finally, TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $204.38.

Charles River Laboratories International Stock Down 1.2 %

NYSE:CRL opened at $164.88 on Thursday. The firm has a 50-day simple moving average of $186.75 and a two-hundred day simple moving average of $197.21. The firm has a market cap of $8.43 billion, a P/E ratio of 20.64, a P/E/G ratio of 5.94 and a beta of 1.38. Charles River Laboratories International has a fifty-two week low of $160.85 and a fifty-two week high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the business earned $2.72 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Analysts predict that Charles River Laboratories International will post 10.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

Institutional investors have recently bought and sold shares of the business. Wolff Wiese Magana LLC bought a new position in shares of Charles River Laboratories International in the third quarter worth about $32,000. Versant Capital Management Inc lifted its holdings in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the period. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).